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Polyglutamine repeatSpinocerebellar ataxia type 3 is caused by a polyglutamine expansion in the ataxin-3 protein, resulting in gain
of toxic function of the mutant protein. The expanded glutamine stretch in the protein is the result of a CAG
triplet repeat expansion in the penultimate exon of the ATXN3 gene. Several gene silencing approaches to
reduce mutant ataxin-3 toxicity in this disease aim to lower ataxin-3 protein levels, but since this protein
is involved in deubiquitination and proteasomal protein degradation, its long-term silencing might not be
desirable. Here, we propose a novel protein modiﬁcation approach to reduce mutant ataxin-3 toxicity by
removing the toxic polyglutamine repeat from the ataxin-3 protein through antisense oligonucleotide-
mediated exon skipping while maintaining important wild type functions of the protein. In vitro studies
showed that exon skipping did not negatively impact the ubiquitin binding capacity of ataxin-3. Our
in vivo studies showed no toxic properties of the novel truncated ataxin-3 protein. These results suggest
that exon skipping may be a novel therapeutic approach to reduce polyglutamine-induced toxicity in
spinocerebellar ataxia type 3.
© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license. Introduction
Spinocerebellar ataxia type 3 (SCA3), also known as Machado–
Joseph disease (MJD), is one of nine known polyglutamine (polyQ)
disorders. PolyQ disorders are autosomal dominant neurodegenera-
tive disorders caused by expansion of a CAG triplet in the coding re-
gion of a gene. This CAG repeat is translated into an extendedMJD, Machado–Joseph disease;
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nc.Open access under CC BY-NC-ND liglutamine stretch in the mutant protein, which causes a gain of
toxic function inducing neuronal loss in various regions throughout
the brain (Bauer and Nukina, 2009). A hallmark of all polyQ disorders
is the formation of large insoluble protein aggregates containing the
expanded disease protein. Whether these large aggregates are neuro-
toxic or neuroprotective is still under debate (Takahashi et al., 2010).
In SCA3, the CAG repeat is located in the penultimate exon of the
ATXN3 gene on chromosome 14q32.1. Healthy individuals have a
CAG repeat ranging from 10 to 51, whereas SCA3 patients have an ex-
pansion of 55 repeats or more (Cummings and Zoghbi, 2000). Trans-
genic mice expressing either a mutant ataxin-3 cDNA fragment (Ikeda
et al., 1996) or the mutated full-length genomic sequence (Cemal
et al., 2002; Goti et al., 2004), showed a clear ataxic phenotype with
a more severe phenotype in the animals carrying larger repeats
(Bichelmeier et al., 2007), demonstrating a relationship between
CAG repeat length and disease severity. The ATXN3 gene codes for
the ataxin-3 protein of 45 kDa, which acts as an isopeptidase and is
thought to be involved in deubiquitination and proteasomal protein
degradation (Burnett et al., 2003; Schmitt et al., 2007; Scheel et al.,
2003). The ataxin-3 protein contains an N-terminal Josephin domain
that displays ubiquitin protease activity and a C-terminal tail with 2
or 3 ubiquitin interacting motifs (UIMs), depending on the isoform
(Goto et al., 1997). Although in the past decade there has beencense. 
Table 1
Antisense oligonucleotide sequences used for transfection and injection.
AON name Sequence (5′–3′)
AON9.1 GAGAUAUGUUUCUGGAACUACC
AON9.2 GCUUCUCGUCUCUUCCGAAGC
AON10 GCUGUUGCUGCUUUUGCUGCUG
Control AON UCCUUUCAUCUCUGGGCUC
mAON9.1 GCUUCUCGUCUCCUCCGCAGC
mAON10 GAACUUGUGGUCGGUCUUUCAC
Scrambled AON CUGAACUGGUCUACAGCUC
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2011), it is still not completely understood how the ataxin-3 polyQ
expansion results in the observed pathology.
Themost promising recent therapeutic strategy under development
for polyQ disorders is reducing levels of mutant polyQ proteins using
RNA interference (RNAi) and antisense oligonucleotides (AONs). As po-
tential gene silencing treatment for SCA3, non-allele speciﬁc reduction
of ataxin-3 has been tested in both mice (Schmitt et al., 2007) and
rats (Alves et al., 2010). The treated rodents were viable and displayed
no overt phenotype, suggesting that ataxin-3 is a non-essential protein.
However, ataxin-3 might also have a protective role, since in ﬂies
ataxin-3 was found to alleviate neurodegeneration induced by mutant
polyQ proteins (Warrick et al., 2005). Whether this is also true in
humans is not known. The results in ﬂies favor selective inhibition of
mutant ataxin-3 protein levels over a total reduction of ataxin-3 protein
levels. Successful allele-speciﬁc reduction of the mutant ataxin-3 tran-
script was shown using lentiviral small hairpin RNAs directed against
a single nucleotide polymorphism (SNP) in the ATXN3 gene in vitro
(Miller et al., 2003) and in vivo (Alves et al., 2008; Nobrega et al.,
2013). However, this approach is limited to SCA3 patients carrying a
heterozygous SNP in the ATXN3 gene. Semi-allele-speciﬁc reduction of
mutant ataxin-3 has also been achieved by targeting the expanded
CAG repeat using single stranded AONs in vitro (Evers et al., 2011; Hu
et al., 2009; Hu et al., 2011).
We here introduce a novel way to reduce toxicity of the ataxin-3
protein through protein modiﬁcation. Using AONs it is possible to
mask exons in the pre-mRNA from the splicing machinery resulting
in exclusion of the targeted exon (Spitali and Aartsma-Rus, 2012;
Zalachoras et al., 2011). If the reading frame remains intact, subse-
quent translation yields an internally truncated protein. This has the
major advantage that the polyQ-containing part of the protein is
removed, while maintaining global ataxin-3 protein levels. AON-
mediated exon skipping is a promising therapeutic tool that is already
in phase II/III clinical trial for Duchenne muscular dystrophy (DMD)
(van Putten and Aartsma-Rus, 2011; Cirak et al., 2011).
In this study we used 2′-O-methyl modiﬁed AONs with a phos-
phorothioate backbone to induce an in-frame exon skip in the
ataxin-3 pre-mRNA. This resulted in a modiﬁed ataxin-3 protein
lacking the polyQ repeat, while total ataxin-3 protein levels were
unaltered and its functional domains remained intact. We showed
that this modiﬁed protein retains its ubiquitin binding capacity. No
cell death was seen after exon skipping, suggesting this modiﬁed pro-
tein did not induce in vitro toxicity. Injection of a single dose of AONs
in the mouse cerebral ventricle resulted in exon skipping in the cere-
bellum, the brain area most affected in SCA3. These results suggest
exon skipping could be a promising novel therapeutic approach to
reduce polyglutamine-induced toxicity in SCA3.
Material and methods
Cell culture and transfection
Patient derived ﬁbroblasts from SCA3 patients (GM06151, pur-
chased from Coriell Cell Repositories, Camden, USA) and controls
(FLB73, a kind gift from Dr. M.P.G. Vreeswijk, LUMC) were cultured
at 37 °C and 5% CO2 in Minimal Essential Medium (MEM) (Gibco
Invitrogen, Carlsbad, USA) with 15% heat inactivated Fetal Bovine
Serum (FBS) (Clontech, Palo Alto USA), 1% Glutamax (Gibco) and
100 U/ml penicillin/streptomycin (P/S) (Gibco). Mouse myoblasts
C2C12 (ATCC, Teddington, UK) were cultured in Dulbecco's Modiﬁed
Eagle Medium (DMEM) (Gibco) with 10% FBS, 1% glucose, 2% Glutamax
and 100 U/ml P/S.
AON transfection was performed in a 6-well plate with 3 μl
of Lipofectamine 2000 (Life Technologies, Paisley, UK) per well.
AON and Lipofectamine 2000 were diluted in MEM to a total volume
of 500 μl and mixtures were prepared according to the manufacturer'sinstruction. Four different transfection conditions were used: 1) trans-
fection with 1–200 nM AONs, 2) transfection with non-relevant
h40AON2 directed against exon 40 of the DMD gene (Control AON)
(Aartsma-Rus et al., 2002), 3) transfection with scrambled AON
(Scrambled), and 4) transfection without AON (Mock) (for AON
sequences, see Table 1). Mixtures were added to a total volume of
1 ml of MEM. Four hours after transfection, medium was replaced
with fresh medium containing 5% FBS. All AONs consisted of 2′-
O-methyl RNA and contained a full-length phosphorothioate modiﬁed
backbone (Eurogentec, Liege, Belgium).
Plasmids and mutations
Full length as well as AON9.2 and AON10 induced skipped
ataxin-3 fragments were PCR-ampliﬁed with ATXN3-speciﬁc primers
(see Table 2) and cloned into pIVEX 1.4 WG vector that contained 6
His-tags (His6-ataxin-3 full length and His6-ataxin-3Δ59aa, respec-
tively). Three microgram of vector DNA was used as template for
cell free protein production using the RTS 100 kit together with the
RTS ProteoMaster (Roche). His6-tagged beta-glucuronidase (GUS)
(5 Prime) was taken along as control vector.
Leucine to alanine mutations in the UIMs were performed using the
QuikChange II Site-Directed Mutagenesis kit (Agilent Technologies,
Waldbronn, Germany) following manufacturer's instructions, using
forward and reverse primers containing the desired mutation
(see Table 2).
RNA analysis
Twenty four hours after the ﬁrst transfection, total RNAwas isolat-
ed from cells using the Aurum Total RNA Mini Kit (BioRad, Hercules,
USA), with an on-column DNase treatment for 30 min. Brain tis-
sue was homogenized using ceramic MagNA Lyser beads (Roche,
Mannheim, Germany) by grinding in a Bullet Blender (Next Advance,
Averill Park, USA) according to manufacturer's instructions. RNA was
eluted in a 40 μl elution buffer and cDNA was synthesized from 1 μg
total RNA using the Transcriptor First Strand cDNA Synthesis Kit
with Random Hexamer primers at 65 °C (Roche).
PCR was performed using 2 μl cDNA, 10× PCR buffer with 1.5 mM
MgCl2 (Roche), 0.25 mM dNTPs, 10 pmol of both forward and reverse
primer (Eurogentec), 1 U FastStart Taq DNA Polymerase (Roche), and
PCR grade water to a ﬁnal volume of 20 μl. PCR was performed with
primers for human andmouse ataxin-3 (see Table 2). The PCR program
started with a 4 min initial denaturation at 95 °C, followed by 35 cycles
of 30 s denaturation at 95 °C, 30 s annealing at 59 °C, and 45 s elonga-
tion at 72 °C, after which a ﬁnal elongation stepwas performed at 72 °C
for 7 min. Lab-on-a-Chip was performed on the Agilent 2100
Bioanalyzer (Agilent Technologies), using the Agilent DNA 1000 Kit.
The qPCR was performed on RNA extracted from tissue isolated
from mouse brain, using 2 μl of 5 times diluted cDNA, 20 times
EvaGreen-qPCR dye (Biotium, Hayward, USA), 10 times PCR buffer
with 1 mM MgCl2 (Roche), 0.25 mM dNTPs (Roche), 2.5 pmol for-
ward primer, 2.5 pmol reverse primer, 0.35 U FastStart Taq DNA Poly-
merase (Roche), and PCR grade water to a total volume of 10 μl.
Primer pairs located in various exons of ataxin-3 were selected for
Table 2
Primer sequences used for Sanger sequencing, mutagenesis, and (quantitative) RT-PCR.
Target Species Primer name Application Sequence (5′–3′)
ATXN3 Human hATXN3Ex8Fw1 RT-PCR CCATAAAACAGACCTGGAACG
ATXN3 Human hATXN3Ex11Rev1 RT-PCR ACAGCTGCCTGAAGCATGTC
ATXN3 Human hATXN3_SDM_L229AFw Mutagenesis ACGAAGATGAGGAGGATGCGCAGAGGGCTCTGGC
ATXN3 Human hATXN3_SDM_L229ARev Mutagenesis GCCAGAGCCCTCTGCGCATCCTCCTCATCTTCGT
ATXN3 Human hATXN3_SDM_L249AFw Mutagenesis ACATGGAAGATGAGGAAGCAGATGCCCGCAGGGCTAT
ATXN3 Human hATXN3_SDM_L249ARev Mutagenesis ATAGCCCTGCGGGCATCTGCTTCCTCATCTTCCATGT
Atxn3 Mouse mAtxn3Ex7Fw1 RT-PCR AAGAGCAGAGTGCCCTCAAA
Atxn3 Mouse mAtxn3Ex11Rev1 RT-PCR TTTCTAAAGACATGGTCACAGC
Atxn3 Mouse mAtxn3Ex4Fw1 qRT-PCR TGCTTTGAAAGTTTGGGGTTT
Atxn3 Mouse mAtxn3Ex4Rev1 qRT-PCR CTGAGCCTCTGGTACTCTGGA
Atxn3 Mouse mAtxn3Ex9Fw1 qRT-PCR GTCCACAGACATCAAGTCCAGA
Atxn3 Mouse mAtxn3Ex9Rev1 qRT-PCR GTCTCCTCCGCAGCTCTTC
Atxn3 Mouse mAtxn3Ex10Fw1 qRT-PCR AGCAGCAGCAGGAGGTAGAC
Atxn3 Mouse mAtxn3Ex10Rev1 qRT-PCR CGTCCTCCTGAACTTGTGGT
Atxn3 Mouse mAtxn3Ex11Fw1 qRT-PCR ACCGACCACAAGTTCAGGAG
Atxn3 Mouse mAtxn3Ex11Rev2 qRT-PCR CCGAAGCATGTCCTCTTCAC
Rpl22 Mouse mRpl22Ex3Fw1 qRT-PCR AGGAGTCGTGACCATCGAAC
Rpl22 Mouse mRpl22Ex3Rev1 qRT-PCR TTTGGAGAAAGGCACCTCTG
Ywhaz Mouse mYwhazEx4Fw1 qRT-PCR TCAGCAAAAAGGAGATGCAG
Ywhaz Mouse mYwhazEx4Rev1 qRT-PCR TTTCTCTGGGGAGTTCAGGA
Abbreviations: ATXN3, ataxin-3; Rpl22, ribosomal protein L22; Ywhaz, tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide.
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tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation
protein, zeta polypeptide (Ywhaz) and ribosomal protein L22
(Rpl22) were used as reference genes (for primer list, see Table 2).
The qRT-PCRwas performed using the LightCycler 480 (Roche). Initial
denaturation was 10 min at 95 °C, followed by 45 cycles of 10 s dena-
turation at 95 °C, 30 s annealing at 60 °C and 20 s elongation at 72 °C.
The ﬁnal elongation was performed 5 min at 72 °C.
Primer efﬁciencies were determined using LinRegPCR v2012.0
with the raw data ampliﬁcation curves as input. The raw data were
baseline corrected and absolute transcript level expressions (N0)
were calculated as described previously (Ruijter et al., 2009). All sam-
ples were run in triplicate on a plate. On all plates both reference
genes were included to correct for inter-plate variance.
Sanger sequencing
Full length and skipped products were ampliﬁed using primers
ﬂanking ataxin-3 exon 9 and 10 (see Table 2). PCR products were
loaded on agarose gel and bands were extracted using the QIAquick
Gel Extraction Kit (QIAgen, Valencia, USA). The puriﬁed products
were re-ampliﬁed, puriﬁed, and analyzed by Sanger sequencing,
using the Applied Biosystems 96-capillary 3730XL system (Life Tech-
nologies Corporation, Carlsbad, USA) with the Applied Biosystems
BigDyeTerminator v3.1 kit.
Protein isolation, ubiquitin binding assay and Western blotting
Cells were detached from the culture surface with a 0.5% Trypsin/
EDTA solution. After washing twice with HBSS, cells were resuspended
in 200 μl ice cold lysis buffer, containing 15 mMHepes, pH 7.9, 200 mM
KCl, 10 mM MgCl2, 1% NP40, 10% glycerol, 20 μg/ml BSA, and 1 tablet
complete mini protease inhibitor EDTA free (Roche) per 10 ml buffer.
Next, samples were sonicated 3 times for 5 s using ultrasound with an
amplitude of 60 at 4 °C. After 1 h incubation in a head-over-head
rotor at 4 °C, the extract was centrifuged for 15 min at 10,000 g and
4 °C and the supernatant was isolated. Protein concentrations were de-
termined by the bicinchoninic acid kit (Thermo Fisher Scientiﬁc, Wal-
tham, USA) using Bovine Serum Albumin (BSA) as a standard.
Samples were snap frozen and stored at−80 °C.
His6-ataxin-full length andHis6-ataxin-3Δ59aa proteinswere bound
to TALON metal afﬁnity beads (Clontech) for 30 min. The ataxin-
3-bound beads were incubated at 4 °C with 5 μg poly-ubiquitin chains(Enzo Life Sciences, Farmingdale, USA). Binding reactions contained
15 mM Hepes, pH 7.9, 200 mM KCl, 10 mM MgCl2, 1% NP40, 10%
glycerol, and 20 μg/ml BSA. Beads were washed extensively and
bound proteins were removed from the beads by 2 h incubation at
23 °C with 2 μg Factor Xa Protease (New England Biolabs, Ipswich,
United Kingdom) per reaction.
Protein extracts were separated by SDS-PAGE, with 10% acryl/
bisacrylamide 1:37.5 separating gels, or Any kD precast TGX gels
(BioRad). For each gel the PageRuler prestained protein ladder (Ther-
mo Fisher Scientiﬁc) was used as marker. Electrophoresis was
performed until the lowest marker reached the bottom of the gel.
Gels were blotted onto nitrocellulose membranes using the Transblot
Turbo (BioRad) for 30 min at 2.5 A. Membranes were blocked with
Tris Buffered Saline (TBS) containing 5% non-fat milk powder
(Proﬁtar Plus, Nutricia, Zoetermeer, the Netherlands).
The mouse SCA3-1H9 antibody was used for detecting ataxin-3
(Millipore, Billerica, USA), dilution 1:1000, or rabbit His-tag 2365
(Cell Signaling Technology, Danvers, USA). To detect expanded
polyQ stretches we used mouse 1C2 (Eurogentec), dilution 1:500.
To detect ubiquitin chains, we used rabbit ubiquitin–protein conju-
gates (Enzo Life Sciences), diluted 1:2000. Secondary antibodies
were goat α-mouse-IRDye800, goat α-rabbit-IRDye800 (LI-COR Bio-
sciences, Lincoln, USA), and goat α-mouse-horseradish peroxidase
(HRP) (Santa Cruz Biotechnology, USA), diluted 1:5000 in block buf-
fer. Horseradish peroxidase was activated by ECL+ reagent (GE
Healthcare, Buckinghamshire, United Kingdom) to visualize positive
staining on ﬁlm or an Odyssey scanner (LI-COR) was used to visualize
infrared bands. Intensities of protein bands were quantiﬁed using Od-
yssey software. The skipping efﬁciencies were calculated as described
in the calculations and statistical analysis paragraph.
AON injection into mice
Mouse ataxin-3 speciﬁc AONs (mAON9.1 and mAON10) and
scrambled control AONs (Table 1) were injected in anesthetized
12–14 week old C57bl/6j male mice (Janvier SAS, France). Animals
were singly housed in individually ventilated cages (IVC) at a
12 hour light cycle with lights on at 7 am. Food and water were avail-
able ad libitum. All animal experiments were carried out in accor-
dance with the European Communities Council Directive 86/609/
EEC and the Dutch law on animal experiments and were approved
by the Leiden University animal ethical committee (protocol number:
12186). A total of 40 μg AON mix diluted in 5 μl sterile saline was
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1.5 mm medio-lateral, and −2.5 mm dorso-ventral relative to
bregma, using borosilicate glass micro-capillary tips connected to
a Hamilton syringe (5 μl, 30 gauge). The Hamilton syringe was
connected to an injection pump (Harvard apparatus, Holliston,
MA, USA), which controlled the injection rate set at 0.5 μl/min.
After 7 days the mice were sacriﬁced and the brains were isolated
and frozen for qRT-PCR analysis.
Calculations and statistical analysis
RNA and protein skipping percentages were calculated using the
following formula: Skipping% = (molarity skipped product / (total
molarity full length product + skipped product)) ∗ 100%. The skip-
ping percentages were analyzed using a paired two-sided Student
t-test. Differences were considered signiﬁcant when P b 0.05.
Results
AON mediated skipping of ataxin-3 exon 9 and 10 in vitro
The CAG repeat in the ATXN3 gene is located in exon 10, which is
119 nucleotides in length. Thus skipping will disrupt the reading
frame. To preserve the reading frame exon 9 (97 nucleotides) and
10 need to be skipped simultaneously. Various AONs were designed
targeting exon internal sequences of ataxin-3 exon 9 and 10 and
transfected in human ﬁbroblasts (Table 1). PCR analysis revealed a
97 nucleotide skip after transfection with 100 nM of AON9.1 (efﬁ-
ciency = 59.2% ± 1.0%) (Figs. 1A and B). Sanger sequencing con-
ﬁrmed that this was a skip of exon 9. Transfection with 100 nM
AON9.2 resulted in a skip of 55 nucleotides (efﬁciency = 62.3% ±
3.7%) instead of the anticipated 97 nucleotides (Figs. 1A and C). Sang-
er sequencing revealed that this fragment was a partial skip product
that still contained the 5′ part of exon 9. In silico analysis showed
the existence of a cryptic 5′ splice site AG|GTCCA in exon 9 that
could explain the occurrence of this shorter fragment (Zhang,
1998). Successful skipping of exon 10 was achieved with 50 nM
AON10 (efﬁciency = 96.3% ± 0.3%) (Figs. 1A and D), as conﬁrmed
by Sanger sequencing.
Co-transfection of AON9.1 and AON10 and AON9.2 and AON10
resulted in a skip of respectively 216 and 174 nucleotides (Fig. 2).
The efﬁciency of the AON9.1 and AON10 induced double skip was
77.0% (±0.9%) in control ﬁbroblasts (Figs. 2D and E). The efﬁciency
of AON9.2 and AON10 co-transfection was 97.8% (±0.8%) in control
ﬁbroblasts (Figs. 2D and E). The unexpected in-frame partial skip of
exon 9 with AON9.2 resulted in an alternative approach to remove
the CAG repeat containing exon from the ataxin-3 transcript (Fig. 2).A B
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Fig. 1. Single exon skipping of ataxin-3 pre-mRNA in vitro. Control ﬁbroblasts were transfect
after 24 h. (A) Agarose gel analysis of the ataxin-3 transcript with primers ﬂanking exon
resulted in a product lacking the entire exon 9 (AON9.1, white arrowhead) or lacking the
resulted in a product lacking exon 10 (three white arrowheads). Fibroblasts were tra
Lab-on-a-Chip analysis was performed to calculate exon skip levels for (B) AON9.1, (C) A
*P b 0.05, **P b 0.01, ***P b 0.001, relative to mock transfection, n = 4.Modiﬁed ataxin-3 protein maintains it ubiquitin binding capacity
To investigate if AON transfection resulted in a modiﬁed ataxin-3
protein, control and SCA3 ﬁbroblasts were transfected with AONs
targeting exon 9 and 10 and protein was isolated three days after
transfection. We did not see a negative effect on cell viability after
AON treatment in either control or SCA3 ﬁbroblasts (Fig. S1). Western
blot analysis using an ataxin-3-speciﬁc antibody revealed a modiﬁed
band of approximately 35 kDa after the complete skip of exon 9 and
10 (ataxin-3 Δ72aa) (Fig. 3A); 11.4% (±5.1%) and 6.2% (±1.9%) of
total ataxin-3 protein levels consisted of this modiﬁed ataxin-3
Δ72aa protein, in respectively control and SCA3 ﬁbroblasts (Figs. 3B
and C).
The partial exon skip resulted in a novel 37 kDa protein (ataxin-3
Δ59aa) (Fig. 3A). 27.1% (±9.0%) and 15.9% (±3.2%) of total ataxin-3
protein levels consisted of this 59 amino acids shorter ataxin-3
protein, in respectively control and SCA3 cells (Figs. 3B and C). The
ataxin-3 Δ72aa protein was also formed, suggesting that AON9.2
and AON10 transfection also resulted in some ataxin-3 Δ72aa protein.
The consistent lower percentage of exon skipping in SCA3 cells were
caused by the lower AON transfection efﬁciencies in the diseased cells
as compared to control cells.
A signiﬁcant reduction in expanded polyQ containing ataxin-3
was shown using the 1C2 antibody, that recognizes long glutamine
stretches (Trottier et al., 1995) (Fig. 3A) in the samples with the full
and partial exon skip approaches. This indicates a reduction of ex-
panded polyQ-containing ataxin-3 in SCA3 patient derived ﬁbroblasts
after AON transfection.
The polyQ repeat in the ataxin-3 protein is located between the
second and third UIM (Fig. 4A). Both full and partial exon skip
approaches resulted in the removal of the polyQ repeat, preserving
the Josephin domain, nuclear export signal (NES), and UIMs. To in-
vestigate whether the ubiquitin binding capacities of the UIMs in
ataxin-3 are still intact after protein modiﬁcation, poly-ubiquitin
chains were incubated with puriﬁed cell free produced full-length
ataxin-3 and ataxin-3 Δ59aa protein. As negative controls, we pro-
duced 3 different ataxin-3 protein products containing 1 amino acid
substitutions from leucine (L) to alanine (A) in UIM 1 (L229A),
UIM 2 (L249A), or both (L229A/L249A) (Fig. 4B). Single amino acid
changes in UIM 1 (L229A) already showed reduced binding of
ataxin-3 to poly-ubiquitin chains, whereas double UIM mutated
ataxin-3 (L229A/L249A) resulted in a nearly complete elimination
poly-ubiquitin binding (Fig. 4C). This is consistent with previously
described data (Burnett et al., 2003). The negative HIS control protein
did not bind ubiquitylated proteins as expected. Ataxin-3 Δ59aa
bound poly-ubiquitin chains comparable to full-length ataxin-3, indi-
cating that its ubiquitin binding capacity after protein modiﬁcation is
still intact (Fig. 4C).DC
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To examine ataxin-3 exon skipping in the mouse brain and to de-
termine if the modiﬁed protein is not harmful, we designed AONs
speciﬁc to the mouse sequence. Since mice do not exhibit the cryptic
splice site that is responsible for the partial exon 9 skip in the human
transcript, we only investigated the full skip of exon 9 and 10. Trans-
fection of 200 nM of each murine AON9 (mAON9) and AON10
(mAON10) in mouse C2C12 cells showed a skip of both exons with
an efﬁciency of 31.7% (±2.4%) (Fig. 5A). Sanger sequencing con-
ﬁrmed this in-frame double exon skip (Fig. 5B). Transfection with
mAON9 and mAON10 resulted in formation of a modiﬁed protein of
34 kDa (Fig. 5C).
Next, a single intra-cerebral ventricular (ICV) injection was ad-
ministered of 40 μg ataxin-3 AON mix (20 μg per AON) or 40 μg
scrambled AON. After 7 days the mice were sacriﬁced and skipping
efﬁciency in the cerebellum was assessed by qRT-PCR (Fig. 6). Exon
9 was found signiﬁcantly reduced by 44.5% (±7.6%) and exon 10
was reduced by 35.9% (±14.1%) after a single ICV injection of AONs
as compared to scrambled AON. Exon 4, upstream, and exon 11,downstream of the area targeted for skipping were not reduced, dem-
onstrating a speciﬁc skip of ataxin-3 exon 9 and 10 in vivo.
Discussion
In the current study we show a novel approach to reduce toxicity
of the mutant ataxin-3 protein through skipping of the CAG repeat
containing exon in the ataxin-3 transcript. The resulting modiﬁed
ataxin-3 protein lacks the polyQ repeat that is toxic when expanded,
but maintains its ubiquitin binding properties. ICV administration
of these AONs in mice resulted in skipping of the CAG repeat-
containing exon in the cerebellum of control mice, proving distribu-
tion and efﬁciency of ataxin-3 exon skipping after ICV injection
in vivo.
There was no negative effect on cell viability after AON treatment
in both control and SCA3 ﬁbroblasts and also no overt toxicity in vivo.
There are several known important functional domains in ataxin-3
that have been implicated to be involved in the SCA3 pathogenesis.
Skipping of exon 9 and 10 described here resulted in the removal of
sequences encoding the calcium-dependent calpain cleavage and
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54 M.M. Evers et al. / Neurobiology of Disease 58 (2013) 49–56nuclear localization signal (NLS), both located in exon 9. Following to
the weak NLS located in the C-terminus (Macedo-Ribeiro et al., 2009),
the ataxin-3 protein has two strong NES located at the N-terminal
part (Macedo-Ribeiro et al., 2009). In SCA3 it is thought that proteo-
lytic cleavage of mutant ataxin-3 results in C-terminal fragments
lacking the NES but containing the polyglutamine stretch, resulting
in localization of the toxic C-terminal fragments into the nucleus
and formation of nuclear inclusion bodies (Bichelmeier et al., 2007;
Colomer Gould et al., 2007). Recent studies in a mutant N-terminal
ataxin-3 mouse model showed that N-terminal fragments, lacking
the NLS, reside in the cytosol and form cytoplasmic inclusion bodies
with subsequent neuronal degeneration (Hubener et al., 2011). Both
above described mutant C- and N-terminal ataxin-3 fragments could
be the result of calpain cleavage at amino acid 260 (Haacke et al.,
2007). Skipping of exon 9 and 10 will also result in the removal of
an arginine/lysine-rich motif around amino acid 285 that was found
to be a potential valosin containing protein (VCP) binding domain
(Boeddrich et al., 2006; Doss-Pepe et al., 2003). The ataxin-3-VCP
complex is thought to be involved in assisting targeted proteins to
the proteasome (Wang et al., 2006). In ﬂies, co-expression of mutant
ataxin-3 and VCP, resulted in alleviation of ataxin-3 aggregation and
neurotoxicity in photoreceptor neurons (Boeddrich et al., 2006).
Whether the removal of the VCP binding domain by exon skipping
causes impaired degradation of target substrates needs to be assessed
in future studies.
As potential gene silencing treatment for SCA3, both non-allele
and allele speciﬁc reduction of (mutant) ataxin-3 have been tested.
The main advantage of the AON-based protein modiﬁcation approach
compared to existing gene silencing approaches is the preservation of
overall ataxin-3 transcript and protein levels. Only the polyQ stretchand a small portion of the surrounding amino acids of the protein
are removed and the N-terminal Josephine domain and C-terminal
ubiquitin binding motifs are preserved. We validated this by showing
that the modiﬁed ataxin-3 protein retains its normal ubiquitin bind-
ing function. Furthermore, the exon skipping approach described
here has the advantage that one set of AONs can be applied to all
SCA3 patients. This in contrast with a previously described SNP-
speciﬁc approach (Miller et al., 2003; Alves et al., 2008) that is only
applicable for 70% of the patients who have the targeted SNP in
their ATXN3 gene (Gaspar et al., 2001).
That AONs are a promising therapeutic tool was recently shown in
phase I and phase I/II clinical trials in DMD (Goemans et al., 2011;
Cirak et al., 2011). As treatment for neurodegenerative disorders,
AONs with a phosphorothioate backbone are very promising and
are currently tested in phase I and phase I/II clinical trials for
amyotrophic lateral sclerosis (ClinicalTrials.gov, 2009) and, more re-
cently, a phase I trial has been initiated for spinal muscular atrophy
(Rigo et al., 2012). After injection into the cerebrospinal ﬂuid in
non-human primates, AONs diffuse to the brain areas that are affect-
ed most in SCA3 patients, which are the cerebellum, basal ganglia,
and pons (Kordasiewicz et al., 2012). In transgenic HD mice, the
most pronounced mutant huntingtin protein reduction was seen
after AON infusion for a limited period of time. Furthermore, several
months after the last AON infusions there were sustained phenotypic
improvements (Kordasiewicz et al., 2012).
The above results are very promising but future experiments will
have to determine the best route of administration to the brain, opti-
mal dosage, and treatment regime. Future experiments are required
to evaluate whether polyQ skipping improves the SCA3 induced
phenotype using transgenic SCA3 mice. Furthermore, it will also be
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56 M.M. Evers et al. / Neurobiology of Disease 58 (2013) 49–56necessary to assess whether the modiﬁed ataxin-3 protein is not toxic
in vitro and in vivo and whether exon skipping results in altered local-
ization, function, or aggregation.
In conclusion, we show that it is possible to remove the toxic
polyQ repeat from a polyQ disease-causing protein and that this
modiﬁed ataxin-3 protein exhibits regular ubiquitin binding. We
also show the in vivo potential of this approach as CAG repeat-
containing exon skip in the cerebellum was seen after a single ICV
injection.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.nbd.2013.04.019.
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